ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAlessandra Gennari, Nadia Harbeck, Frédérique Penault‐Llorca et al.|Annals of Oncology|2021Cited by 1.4k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock‐Ah Im, Debu Tripathy, Yen‐Shen Lu et al.|New England Journal of Medicine|2019Cited by 1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Seock‐Ah Im et al.|The Lancet Oncology|2018Cited by 1k
Cycling cancer persister cells arise from lineages with distinct programsYaara Oren, Aviv Regev, Michael Tsabar et al.|Nature|2021Cited by 514
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al.|Annals of Oncology|2021Cited by 294